A 65-year-old man with metastatic melanoma was started on immunotherapy, switched to alternative targeted therapy and developed disseminated intravascular coagulation. This case underscores the complexity of interpreting and managing side effects of novel therapies in cancer care, identification of progression versus pseudoprogression and challenges in sequencing treatments in metastatic melanoma.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129100 | PMC |
| http://dx.doi.org/10.1136/bcr-2016-216681 | DOI Listing |
Publication Analysis
Top Keywords
metastatic melanoma
12
challenges immunotherapy
4
immunotherapy metastatic
4
melanoma 65-year-old
4
65-year-old man
4
man metastatic
4
melanoma started
4
started immunotherapy
4
immunotherapy switched
4
switched alternative
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!